TABLE 5.

Comparison between Aβ immunotherapy in animal models and human clinical trials.

		Mice					Clinical trials
Vaccine (mouse version)	Target	Model	Aβ /Plaque reduction	CAA	MiH	Cog	Plaques	CAA	CSF-pTau	vMRI loss	ARIA-E	Cog
AN-1792	Human Aβ1–42 +QS-21	PDAPP	N/A	N/A	N/A	N/A	Decrease	Increase	N/A	N/A	6%	No
CAD-106	Aβ1–6+bacterio-phage Qβ	APP, APP24, APP23, rhesus monkeys	80%	Increase	No	N/A	Decrease	Increase	No change	N/A	0	N/A
ACC-01	Aβ1–7 +QS-21	Non-human primates	N/A	N/A	N/A	N/A	No change	N/A	No change	No change	0.8–6%	No change
AD-02	fibrillar Aβ1-6 + Alum	Tg2576	70%	No change	No	Yes (MWM, CFC)	N/A	N/A	N/A	Increase	0	No change
Bapi (3D6)	Aβ1–5	PDAPP	86%	Decrease	Increase	No (MWM)	Decrease	N/A	Decrease	No change	15%	No change
Solz (M226)	Soluble Aβ16–20	PDAPP, J20	Variable	N/A	No	Variable	No change with PET and IHC	230% increase	No change	No change	0.5–1.1%	Significant change in ADAS-Cog 11
Cren	Conformation Aβ16–24	hAPP(V7171)/PS1, Tg256	Variable	N/A	N/A	N/A	No change	N/A	No change	No change	0.60%	Initial decline
Gant	Conformation Aβ aggregates	PSAPP, APP Tg2576	36–70%	No change	No	No (MWM)	Decrease	N/A	Decrease	No change	18–35%	No change
Don (mE8)	Aβ(p3–42)	PDAPP	53%	No change	No	N/A	78%	N/A	Decrease	No change	25%	32% change in iADRS
Lecan (mAb-158)	Protofibrils	Tg-ArcSwe	40%	N/A	N/A	No (MWM)	80%	N/A	Decrease	No change	10%	Significant change in ADAS-Cog14
Adu	Aβ3–6	TG2576	70%	N/A	N/A	N/A	Decrease		Decrease		34–35%	22% change of CDR-SOB
UB-311	Aβ1–14	Macaques			No

CAA, cerebral amyloid angiopathy; MiH, microhaemorhage; Cog, Cognition; vMRI, volumetric magnetic resonance imaging; MWM, morris water maze; CFC, contextual fear conditioning; IHC, immunohistochemistry.